ProductsMulti-source72°

OpenAI 与 Perturb、Scripps 合作,GPT-Rosalind 智能体集群助力神经退行性疾病药物研发

Why we picked it

OpenAI 和 Perturb、Scripps 让几千个智能体并行跑,32 分钟就从几百万个脑细胞数据里挖出胆固醇转运这个新药线索。做科研自动化的、做药物发现的朋友都该看看这个智能体工作流怎么搭的。

OpenAI 联合 Perturb 和 Scripps Research 发布 GPT-Rosalind 智能体在神经退行性疾病研究中的进展。数千个 GPT-Rosalind 智能体并行工作,将数百万小鼠脑细胞的基因表达数据与科学文献关联,整个过程只用了 32 分钟。

Image · OpenAI
Body

具体案例围绕 Perry 综合征相关基因 DCTN1:小鼠脑数据中该基因被扰动后,参与胆固醇合成的基因表达上升。GPT-Rosalind 由此提出一个可检验的机制假设——胆固醇可能没有输送到神经元需要的位置,恢复胆固醇转运或许能保护神经元免于退化。这为科学家提供了明确的实验方向。

双方已宣布扩大合作范围,用同样的智能体工作流寻找新的药物靶点,把 AI 生成假设、湿实验验证的闭环推向更多疾病领域。

Original · OpenAI

How AI is helping scientists uncover new leads for understanding and treating neurodegenerative diseases—and the brain research behind our collaboration with @perturbai_tx and @scrippsresearch :

Industry Coordinates & Source Verification

This report is categorized under AITOP's "Products" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include OpenAI, GPT-Rosalind, Perturb, Scripps Research.

Source attribution: curated from OpenAI (@OpenAI (@OpenAI)). Cross-source corroboration: 11 independent sources have covered this development (including GitHub, Vercel AI, Guillermo Rauch), confirming industry-wide signal strength.